BLOG

Treatment for dangerous snoring prevents deaths from heart disease.

11 September, 2023

People suffering with obstructive sleep apnoea (OSA) can reduce their risk of dying
from cardiovascular disease if they use a continuous positive airway pressure (CPAP) machine at
night, according to research presented at the European Respiratory Society International Congress in
Milan, Italy [1].

CPAP may also work better than a weight loss drug in reducing the build-up of plaque in the arteries
around the heart, according to a pilot study also presented at the European Respiratory Society
International Congress [2].

People with OSA often snore loudly, their breathing starts and stops during the night, and they may
wake up several times. This can lower the amount of oxygen in the blood and cause tiredness. It can
also increase the risk of high blood pressure, stroke, heart disease and type 2 diabetes.

CPAP machines are offered to people with OSA to help them sleep better. They work by blowing air
through a face mask throughout the night to prevent the user’s airways from closing.

The heart disease study was presented by Dr Jordi de Batlle from Institute de Recerca Biomèdica de
Lleida (IRBLleida), Lleida, Spain. He and his colleagues tracked down all 3,638 OSA patients living in
Catalonia who had chosen to stop using CPAP in 2011. They compared these to a similar group of
3,638 OSA patients who continued to use CPAP until at least 2015 or until death.

When they compared the two groups, they found that those who continued to use CPAP had a 40%
lower risk of dying by any cause, a 36% lower risk of dying from cardiovascular disease and an 18%
lower risk of being hospitalized with cardiovascular disease.

Dr de Batlle said: “Our results suggest that CPAP treatment can help most OSA patients by
preventing cardiovascular problems such as heart disease and stroke. This is a plus, as CPAP
treatment already helps most OSA patients by reducing sleepiness and improving their quality of life.
Based on these findings, we should encourage people with OSA to keep using their CPAP machines.”

The pilot study was presented by Dr Cliona O’Donnell, a specialist registrar in respiratory medicine at
St. Vincent’s University Hospital and University College Dublin, Ireland. She and her colleagues
conducted a study with 30 patients suffering from OSA who underwent a computerized tomography
(CT) coronary angiogram to assess any signs of narrowing in the blood vessels that supply the heart.

The patients were then randomly assigned to 24 weeks of treatment either using a CPAP machine at
night, or injections with weight loss drug liraglutide, or both together.

Patients who showed signs of coronary artery disease in their first scan underwent a repeat scan at
the end of the 24 weeks of treatment. Researchers used an artificial intelligence program to analyze
the patients’ scans.

The patients who were treated with CPAP and those treated with CPAP and weight loss injections
experienced reductions in the plaque build-up in their arteries and a reduction of inflammation in
their aorta (the main artery that carries blood from the heart to the rest of the body). Patients who
were treated with weight loss injections only did not experience these effects.

Dr O’Donnell said: “Continuous positive airway pressure works by keeping patients’ airways open
while they sleep. This stops fluctuations in oxygen levels in the blood that can exacerbate
cardiovascular disease.

“Although this is a pilot study, meaning we cannot draw firm conclusions, we found improvements in
some early signs of cardiovascular disease with CPAP treatment. This should now be further
evaluated in larger studies.”